Biogen Inc.
CIK: 0000875045
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
APLS
Apellis Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About BIOGEN INC.
BIOGEN INC. (SEC CIK 0000875045) files insider reports with the SEC as Apellis Pharmaceuticals, Inc. (APLS).
Signal8 holds 1 ownership filing by BIOGEN INC., a Form 3, filed on Apr 6, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on BIOGEN INC.'s filings is in CAMBRIDGE, MA.
Other insiders filing for Apellis Pharmaceuticals, Inc. (APLS)
- Dunlop A. Sinclair, Director
- Chopas James George, VP/Chief Accounting Officer
- Dolsten Mikael, Director
- MELTZER LESLIE, Chief Research and Development
- FONTEYNE PAUL R., Director
- Sullivan Timothy Eugene, Chief Financial Officer